“Right-to-try” sounds like the kind of thing you’d see stitched on a throw pillow in a very optimistic waiting room. Who could argue with it? If you’re out of options, shouldn’t you get a shot at somethinganythingbefore the clock runs out? That emotional logic is real. So is the fear behind it.

But policy isn’t a slogan contest, and “right-to-try” is a slogan with a trapdoor. When the idea marched toward federal law, it was sold as a shortcut around bureaucrats: a way for people with life-threatening illness to access experimental drugs faster, without the Food and Drug Administration (FDA) “getting in the way.”

Here’s the uncomfortable twist: the FDA usually wasn’t the main thing in the way. The big barriers were (and still are) drug-company supply decisions, eligibility rules, costs, logistics, and the brutal reality that most early-stage drugs don’t workand some harm the very people who can least afford harm. So the “right” being offered wasn’t a right to receive anything. It was mostly a right to ask, and then be told “no” faster.

In other words: a lot of heat, not much light. And when a bill like that becomes “a giant step” toward federal law, it’s worth asking who benefits from the headlineand who pays the price when hope gets turned into legislative theater.

What “right-to-try” actually is (and how it took that “giant step”)

The modern “right-to-try” movement took off at the state level first, framing access to investigational treatments as a matter of personal freedom and local control. By the time Congress took up federal legislation, many states had already passed versions of these laws.

Federally, the idea advanced quickly. A Senate bill (S. 204) was introduced in early 2017 and moved through Congress over the next year and a half. The House also advanced its own version (H.R. 5247). By spring 2018, “right-to-try” had become a bipartisan talking point and a presidential priority. On May 30, 2018, the federal Right to Try Act was signed into law.

That’s the political timeline. The human timeline is messier. The law is named after people facing devastating diseases, and the public story was framed around families confronting the end of life. Those stories are not marketing propsthey’re real. The question is whether the law built around them actually solved the problem it claimed to solve.

Before “right-to-try,” patients already had a pathway: Expanded Access

One reason critics call “right-to-try” a sham is that the U.S. already had an established system for patients who can’t join a clinical trial but want access to an investigational drug: FDA’s Expanded Access program (often called “compassionate use”).

Expanded Access is designed for people with serious or life-threatening disease who have no comparable or satisfactory alternatives and cannot access a clinical trial. It is not a “free-for-all,” and it’s not supposed to be. The whole point is to create a supervised path that balances urgent need with basic safety checks and clear responsibilities.

What Expanded Access does well (and why it matters)

• It has a track record. FDA has reported consistently high authorization rates for Expanded Access requests.
• It includes oversight. FDA review helps assess whether the potential risks are reasonable in the patient’s situation, and whether the request is structured responsibly.
• It’s been streamlined. The process for individual patient requests has been simplified over time (including streamlined forms designed for physicians).
• It supports emergencies. In urgent situations, FDA can authorize emergency access rapidly, with paperwork to follow.

None of this guarantees access, because the biggest gatekeeper is still the manufacturer. A company has to be willing and able to provide the drug. But Expanded Access at least creates a supervised channel that can reassure companies, protect patients, and generate more reliable documentation of what happened.

The “right-to-try” promise vs. the “right-to-try” reality

The sales pitch for right-to-try is simple: “Cut the red tape.” In practice, it doesn’t cut the red tape that actually matters. It mainly cuts the red tape that made the story less catchy.

Promise #1: “It’s faster because it bypasses the FDA”

Under the federal Right to Try pathway, FDA does not review or approve individual patient requests. That’s the defining feature. Supporters call this “faster.” Critics call it “less safe.”

But speed was never only about FDA. The slow part is often finding a company contact, persuading the sponsor to say yes, getting the treating physician to coordinate the request, arranging shipment, and managing costs. A law that removes FDA from the decision doesn’t remove any of those steps. It mostly removes one of the few steps designed to protect patients and standardize reporting.

Promise #2: “It creates a right”

Here’s where the word “sham” starts earning its keep. The FDA itself is explicit: the law does not obligate a sponsor/manufacturer to provide the drug. It also doesn’t force a physician to participate, and it doesn’t require insurers to pay. So what is the “right”?

If you’re thinking “a right to submit paperwork into the void,” you are… not wrong. A “right” that depends on voluntary decisions by everyone else isn’t a right in any meaningful sense. It’s a request pathway with better branding.

Promise #3: “It offers access to promising drugs”

“Right-to-try” drugs only need to have completed Phase 1 testingmeaning they’ve cleared the first stage of human testing focused mainly on safety and dosage, not proof that they work. That’s important, because the odds are not great. Many drugs that look promising early either fail later or reveal serious side effects.

For someone with a life-threatening illness, taking a long-shot risk may be a rational choice. But rational choice requires clarity: Phase 1 is not “almost approved.” It’s “we’re still figuring out whether this is even viable.”

Why critics call it cruel: it sells hope while dodging the real problems

Calling something “cruel” isn’t about denying that patients deserve options. It’s about what happens when lawmakers sell an “option” that doesn’t function as advertisedespecially to people who are scared, exhausted, and short on time.

1) It shifts attention away from the real gatekeeper: the manufacturer

Companies control supply, eligibility, staffing, and priorities. They may fear that uncontrolled access could complicate clinical development, create bad press, or divert limited doses away from trials. They may also have legitimate scientific reasons to say no (for example, concerns about safety in very sick patients).

Right-to-try doesn’t solve this. It doesn’t require a “yes.” It doesn’t require a public explanation for a “no.” It doesn’t fund manufacturing scale-up. It doesn’t build patient navigation. It mostly creates a new headline: “You can try!” even if the answer is still “You can’t get it.”

2) It reduces guardrails precisely when guardrails matter most

Expanded Access includes FDA involvement; right-to-try minimizes it. Individual right-to-try requests do not require Institutional Review Board (IRB) review. The law relies on physician certification and written informed consent, but it provides less structure around what informed consent must include.

In a perfect world, every patient would get a thorough, unhurried explanation of risks, unknowns, and alternatives. In the real world, end-of-life medicine is emotionally intense, time-pressured, and full of cognitive bias (including the totally human tendency to hear “experimental” and translate it as “miracle”). That’s exactly when standardized oversight helps.

3) It risks undermining clinical trialsthe engine that creates real options

Clinical trials aren’t just bureaucracy. They are how we learn whether a drug works, what dose is safe, who benefits, and what harms exist. If “right-to-try” is framed as “the better way,” it can weaken trial enrollment or encourage people to chase drugs outside the trial system.

And if patients access drugs in unstructured ways, society learns less from their experience. That’s a problem not because patients “owe” society data, but because future patients deserve better than guesswork.

4) It bakes in a convenient blame story

Politically, “right-to-try” is a neat narrative: if you can’t get the drug, it must be the FDA’s faultor some faceless “system.” That makes for great speeches. It also misleads the public about how access actually works.

Expanded Access already existed, was being improved, and had high authorization rates. The hard part has always been coordinating the request and getting the drug. When legislation pretends the obstacle is mainly FDA paperwork, it distracts from reforms that could genuinely improve access (like better trial availability, better patient navigation, and clearer sponsor policies).

What the federal law requiresand what it conspicuously doesn’t

Under the federal Right to Try framework, a patient must have a life-threatening disease, have exhausted approved treatment options, be unable to participate in a trial involving that drug, and provide written informed consent. The drug must have completed Phase 1, be under an active development program, and not be under clinical hold or discontinued.

The law also includes reporting requirements for sponsors/manufacturers who provide drugs under right-to-try, and FDA posts consolidated summaries of certain right-to-try reporting. But the structure is thinner than the Expanded Access pathway, and many observers have noted that real-world use of right-to-try has been limited.

That limited use is telling. If right-to-try were the revolutionary shortcut it was marketed as, you’d expect it to be crowded. Instead, most clinicians and sponsors still lean on Expanded Access because it is familiar, supervised, and generally workable.

What would help patients more than “right-to-try” theater

If the goal is meaningful accessnot just a comforting headlinepolicy needs to focus on the actual friction points.

1) Make Expanded Access easier to navigate (especially outside big academic hospitals)

Many community physicians don’t have regulatory staff. Programs that help clinicians submit requests and coordinate with sponsors can reduce inequity. FDA’s oncology-focused support efforts (like Project Facilitate) are examples of the kind of practical assistance that turns “possible” into “actually doable.”

2) Increase trial access and modernize eligibility

People are often excluded from trials for reasons that don’t match real-world patients: comorbidities, age, lab values, geography. Better trial design, decentralized trial options, and more thoughtful inclusion criteria can reduce the demand for last-minute hail-mary pathways.

3) Improve sponsor transparency

Patients and physicians waste precious time trying to find out whether a company will even consider access. Clear public policies, designated contacts, and predictable criteria would do more for real access than any slogan.

4) Be honest about what early-stage drugs can do

The most compassionate thing policymakers can do is tell the truth: Phase 1 completion is not a promise. It’s a starting line. Patients deserve hope that is accuratenot hope that is convenient.

If you’re a patient or caregiver: a safer way to think about “one last option”

If someone you love is facing a serious or life-threatening condition, the desire to “try everything” is understandable. The goal is to pair that desire with a process that reduces avoidable harm.

1. Ask about clinical trials first. Trials provide structure, monitoring, and the best chance your experience helps you and informs others.
2. Discuss Expanded Access with your physician. It’s the established pathway and is regulated; many clinicians prefer it for good reasons.
3. Ask the sponsor’s real constraints. If the answer is “we can’t supply,” no law can manufacture doses out of thin air.
4. Get clear on costs. “Experimental” can come with experimental-sized bills. Don’t assume insurance will help.
5. Protect your time and energy. If a path becomes a paperwork marathon with no sponsor support, it may be better to refocus on symptom relief and quality of life.

None of these steps are easy. But they are grounded in how access works in realitynot how it sounds on a podium.

Conclusion: A right-to-try should not be a right-to-be-marketed-to

The push to make “right-to-try” federal law rode on a powerful moral claim: that people facing death deserve the freedom to take risks. That claim has weight. The tragedy is that the law built around it mostly dodged the real work of improving access.

When a policy offers the emotion of action without the substance of change, it isn’t neutral. It can be actively harmfulbecause it raises expectations it cannot meet, redirects attention from better solutions, and lowers guardrails in situations where clarity and protection matter most.

Patients deserve more than a symbolic “right.” They deserve a health system that makes it easier to find trials, easier to request regulated access when trials aren’t possible, and easier to get honest answers fast. Anything less is not compassion. It’s branding.

Experiences on the ground: what “right-to-try” feels like in real life (added section)

Talk to clinicians who’ve actually tried to secure investigational drugs for a patient, and you’ll hear a theme that doesn’t fit neatly into political talking points: the hardest part is almost never “the FDA said no.” The hardest part is getting to a clear answer at all.

A typical experience starts with a patient (or a family member who has become an overnight research librarian) arriving with a printout, a headline, or a hopeful social media post: “This drug is in trialscan we get it?” The physician then has to do three things at once: keep hope alive, keep expectations realistic, and keep the patient safe. That’s already a tightrope. Now add the operational grind: tracking down the right person at a company, finding out whether the product is even eligible, asking whether any doses are available, and learning the sponsor’s internal ruleswhich can be strict, inconsistent, or simply not written down.

Families often assume the problem is government red tape because that’s the story they’ve heard. In the exam room, the story becomes more complicated: sometimes the company is focused on enrolling trials and has limited supply; sometimes it worries about safety in patients who are much sicker than trial participants; sometimes it says yes but needs time for internal approvals; sometimes it says no and offers no timeline. None of that fits on a bumper sticker.

The “right-to-try” label can also distort expectations. People hear “right” and expect entitlement. Then they’re shocked to learn that nobody is obligated to provide the drug. That momentwhen a family realizes the “right” is not a guaranteecan feel like betrayal. Not because anyone acted maliciously in the clinic, but because the law was packaged with an emotional promise it can’t consistently keep.

Clinicians describe another kind of pressure: the quiet fear of being seen as the obstacle. If a physician advises cautionexplaining that Phase 1 doesn’t prove a drug works, or that the risks could outweigh the benefitpatients may interpret that as gatekeeping. It can strain trust at exactly the moment trust is most needed. Good doctors then do what good doctors do: they slow the conversation down, revisit goals, and help families ask better questions, like “What’s the best-case scenario?” and “What does ‘worse’ look like?” and “What are we giving up if we chase this?”

Sometimes the experience is genuinely positivenot because the law waved a wand, but because a sponsor agreed, the care team coordinated smoothly, and the patient tolerated the drug. Even then, the outcome may be ambiguous: stabilization for a short period, side effects that require extra support, or no benefit at all. Families often say the value was not just “we tried,” but “we had a team that helped us try responsibly.” That’s the key: the humane version of last-chance medicine is not less structure; it’s better structure.

The most common “experience,” though, is the slow fade of a lead that never becomes access: unanswered emails, “we’ll get back to you,” eligibility rules that exclude the patient, and time running out. This is where “right-to-try” can feel especially cruel. A headline implies a door has opened, but the family still finds the hallway locked. When hope is scarce, even a symbolic promise can be emotionally expensive.

If there’s a lesson from these real-world experiences, it’s this: access is a system problem, not a slogan problem. The fixes that matter are practicalnavigation support, transparent sponsor policies, improved trial access, and streamlined regulated pathways. That’s not as emotionally satisfying as declaring a “right,” but it’s far more likely to help the next person who walks into a clinic holding hope in both hands.

The post The cruel sham of “right-to-try” takes a giant step towards becoming federal law appeared first on Everyday Software, Everyday Joy.